169 related articles for article (PubMed ID: 21502756)
1. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients.
Takeda Y; Komaba H; Goto S; Fujii H; Umezu M; Hasegawa H; Fujimori A; Nishioka M; Nishi S; Fukagawa M
Am J Nephrol; 2011; 33(5):421-6. PubMed ID: 21502756
[TBL] [Abstract][Full Text] [Related]
2. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
[TBL] [Abstract][Full Text] [Related]
3. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
[TBL] [Abstract][Full Text] [Related]
4. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
Wolf M; Koch TA; Bregman DB
J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
[TBL] [Abstract][Full Text] [Related]
5. New insights into the role of fibroblast growth factor 23 in chronic kidney disease.
Nakai K; Komaba H; Fukagawa M
J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients.
Hryszko T; Rydzewska-Rosolowska A; Brzosko S; Koc-Zorawska E; Mysliwiec M
Ther Apher Dial; 2012 Apr; 16(2):146-51. PubMed ID: 22458393
[TBL] [Abstract][Full Text] [Related]
7. Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.
Maruyama N; Otsuki T; Yoshida Y; Nagura C; Kitai M; Shibahara N; Tomita H; Maruyama T; Abe M
Am J Nephrol; 2018; 47(6):406-414. PubMed ID: 29874654
[TBL] [Abstract][Full Text] [Related]
8. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
[TBL] [Abstract][Full Text] [Related]
9. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
[TBL] [Abstract][Full Text] [Related]
10. Klotho gene, phosphocalcic metabolism, and survival in dialysis.
Torres PU; Prié D; Beck L; De Brauwere D; Leroy C; Friedlander G
J Ren Nutr; 2009 Jan; 19(1):50-6. PubMed ID: 19121771
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
12. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Nephrol Dial Transplant; 2011 Aug; 26(8):2691-5. PubMed ID: 21303965
[TBL] [Abstract][Full Text] [Related]
13. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
Ashikaga E; Honda H; Suzuki H; Hosaka N; Hirai Y; Sanada D; Nakamura M; Nagai H; Matsumoto K; Kato N; Mukai M; Watanabe M; Takahashi K; Shishido K; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):315-22. PubMed ID: 20609185
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
16. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
Stubbs J; Liu S; Quarles LD
Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
[TBL] [Abstract][Full Text] [Related]
17. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
[TBL] [Abstract][Full Text] [Related]
18. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients.
Urena Torres P; Friedlander G; de Vernejoul MC; Silve C; Prié D
Kidney Int; 2008 Jan; 73(1):102-7. PubMed ID: 17943081
[TBL] [Abstract][Full Text] [Related]
19. Normal FGF23 levels in adult idiopathic phosphate diabetes.
Laroche M; Boyer JF; Jahafar H; Allard J; Tack I
Calcif Tissue Int; 2009 Feb; 84(2):112-7. PubMed ID: 19148564
[TBL] [Abstract][Full Text] [Related]
20. Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients.
Jia T; Qureshi AR; Brandenburg V; Ketteler M; Barany P; Heimburger O; Uhlin F; Magnusson P; Fernström A; Lindholm B; Stenvinkel P; Larsson TE
Am J Nephrol; 2013; 37(5):462-71. PubMed ID: 23635517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
